Joining the podcast today is Mark Muzzin, Managing Director, Nexsen, ASX:NXN. Mark will speak about the recent FDA feedback on StrepSure®, the company’s global rollout strategy, and the pathway toward regulatory submission and initial commercialisation.

Podcast Questions

Introduction to company 1. Nexsen is developing rapid point of care diagnostics, can you outline the core focus of the business and the unmet need you are targeting in healthcare?

Strategy 2. With the FDA pre submission feedback now received, how does this shape your regulatory and commercial strategy for StrepSure® moving forward?

Flagship Projects 3. StrepSure® is your lead diagnostic product, what differentiates it from current lab based testing methods and why is this clinic ...